Deals and Financings   Illumina will pay $8 million to acquire GRAIL, a company developing an early screening test for 50 forms of cancer based on methylation technology from Hong Kong 's Cirina; In an exclusive interview, Min Cui, PhD, Managing Partner of Decheng, discussed Decheng's history with Cirina and how the company came to be part of GRAIL; JD Health, a Beijing online healthcare offshoot of China e-commerce giant JD.com, plans to raise $3 billion in a Hong Kong IPO; Sequoia Capital China is raising $2.2 billion for a new yuan-denominated fund, that will invest in healthcare companies along with other industries; Genor Biopharma, a Shanghai biologics company, is conducting a Hong Kong IPO that could raise up to $370 million; Viva Biotech of Shanghai will pay $80 million to acquire fellow drug preclinical CRO SYNthesis Med Chem of Hong Kong; Sperogenix Therapeutics of Beijing in-licensed a CNS drug for a rare disease from Barcelona 's Minoryx Therapeutics in a $78 million agreement; ImmVira Group, a Shenzhen biotech, raised $10 million in a Series B to develop its next-gen genetically modified oncolytic viruses for cancer; BioDuro and Sundia, two pre-clinical China-US CROs, have merged to form one of the largest CRDMOs that has operations in China and the US ; Trials and Approvals   Sinovac Biotech announced the start of a Phase III trial of CoronaVac, its COVID-19 vaccine, in Turkey ; XiangXue Life Sciences received US permission to start a Phase I trial of its high affinity specific T-cell receptor candidate, Company News Legend Biotech of Nanjing announced its CEO, Dr. Fangliang Zhang, was put under house arrest by officials from the China Customs Office. Stock Symbols: (NSDQ: ILMN) (HK: 1873) (NSDQ: LEGN)